Nephrol Dial Transplant (1995) 10: 1963-1974
© 1995 European Renal Association-European Dialysis and Transplant Association
research-article
Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials
1Groningen Institute for Drug Studies (GIDS), Divisions of Nephrology, State University Hospital Groningen, The Netherlands 2Groningen Institute for Drug Studies (GIDS), Divisions of Endocrinology, State University Hospital Groningen, The Netherlands
Correspondence and offprint requests to: Correspondence and offprint requests to: Dick de Zeeuw MD, Associate Professor Nephrology, State University Hospital, Oostersingel 59, 9713 EZ Groningen, The Netherlands
Whether ACE inhibitors (ACEi) differ from other antihypertensives in their efficacy to lower proteinuria is controversial. We therefore performed a meta-analysis of articles on this subject. The secondary objective in our meta-analysis was to study whether there is any difference between diabetic and non-diabetic patients in antiproteinuric response to blood pressure reduction.
To identify all articles we performed a computer search using the bibliographic databases. To minimize publication bias, only trials in which a direct comparison was made between an ACEi and another antihypertensive were included. Studies performed both in diabetic and in non-diabetic patients were eligible. Included were 41 studies, comprising 1124 patients, of which 558 had non-diabetic renal disease. The mean antiproteinuric effect of ACEi was significantly greater than that of their comparator drugs: –39.9% (95% confidence interval: –42.8 to –36.8%) versus –17.0% (–19.0 to –15.1%) respectively (difference 24% (19.5 to 28.6%)). The blood-pressure-lowering effect was equal: –12.0% (–12.8 to –11.2%) versus –11.4% (–11.7 to –11.1%) respectively (difference –0.8% (–1.8 to 0.2%)). Thus it may be concluded that ACEIs confer an antiproteinuric effect beyond that attributable to their blood-pressure-lowering effect. A wide interstudy variation in antiproteinuric response to non-ACEI antihypertensives was observed. Multiple variable regression analysis was performed to assess which factors may explain this heterogeneity. From the comparator drugs, the class was of no importance: calcium-channel antagonists (CCA), ß-blockers, and a rest group of other drug types showed a similar response. Patient characteristics such as initial GFR and blood pressure partly explained the variation in response, but most of it appeared dependent on the blood pressure reduction achieved. Furthermore the type of CCA is of importance, with nifedipine having the least effect. A significantly greater antiproteinuric effect of ‘non-ACEI’ antihypertensives was found in diabetic patients compared to non-diabetics. However, this coincided with a greater blood pressure reduction in diabetics. Adjusted for differences in blood pressure control, diabetics showed even a slightly lesser antiproteinuric response to non-ACEI antihypertensive compared to non-diabetics.
Keywords: angiotensin-converting enzyme inhibitors; beta-blocking agent; calcium-channel blockers; comparative study; meta-analysis; proteinuria
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. S. Gipson, S. F. Massengill, L. Yao, S. Nagaraj, W. E. Smoyer, J. D. Mahan, D. Wigfall, P. Miles, L. Powell, J.-J. Lin, et al. Management of Childhood Onset Nephrotic Syndrome Pediatrics, August 1, 2009; 124(2): 747 - 757. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Levin MD, B. Hemmelgarn MD PhD, B. Culleton MD MSc, S. Tobe MD, P. McFarlane MD PhD, M. Ruzicka MD PhD, K. Burns MD, B. Manns MD MSc, C. White MD, F. Madore MD MSc, et al. Guidelines for the management of chronic kidney disease Can. Med. Assoc. J., November 18, 2008; 179(11): 1154 - 1162. [Full Text] [PDF]
|
|
|
|
 |
|
 R. P Hull and D. J A Goldsmith Nephrotic syndrome in adults BMJ, May 24, 2008; 336(7654): 1185 - 1189. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Burnier Blockade of the renin-angiotensin system for renal future perspectives protection: from history to future perspective Journal of Renin-Angiotensin-Aldosterone System, December 1, 2007; 8(4): 208 - 211. [PDF]
|
|
|
|
 |
|
 A. H. Brantsma, J. Atthobari, S. J.L. Bakker, D. de Zeeuw, P. E. de Jong, R. T. Gansevoort, and for the PREVEND Study Group What Predicts Progression and Regression of Urinary Albumin Excretion in the Nondiabetic Population? J. Am. Soc. Nephrol., February 1, 2007; 18(2): 637 - 645. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M.A. van de Wal, R. T. Gansevoort, P. van der Harst, F. Boomsma, H.W. Thijs Plokker, D. J. van Veldhuisen, P. E. de Jong, W. H. van Gilst, and A. A. Voors Predictors of Angiotensin-Converting Enzyme Inhibitor-Induced Reduction of Urinary Albumin Excretion in Nondiabetic Patients Hypertension, November 1, 2006; 48(5): 870 - 876. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Jacobs Costs and benefits of improving renal failure treatment--where do we go? Nephrol. Dial. Transplant., August 1, 2006; 21(8): 2049 - 2052. [Full Text] [PDF]
|
|
|
|
|
|
M. Ravera, M. Re, L. Deferrari, S. Vettoretti, and G. Deferrari Importance of Blood Pressure Control in Chronic Kidney Disease J. Am. Soc. Nephrol., April 1, 2006; 17(4_suppl_2): S98 - S103. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Pohl, S. Blumenthal, D. J. Cordonnier, F. De Alvaro, G. DeFerrari, G. Eisner, E. Esmatjes, R. E. Gilbert, L. G. Hunsicker, J. B. L. de Faria, et al. Independent and Additive Impact of Blood Pressure Control and Angiotensin II Receptor Blockade on Renal Outcomes in the Irbesartan Diabetic Nephropathy Trial: Clinical Implications and Limitations J. Am. Soc. Nephrol., October 1, 2005; 16(10): 3027 - 3037. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Chiurchiu, G. Remuzzi, and P. Ruggenenti Angiotensin-Converting Enzyme Inhibition and Renal Protection in Nondiabetic Patients: The Data of the Meta-Analyses J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S58 - S63. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. de Zeeuw, G. Remuzzi, H.-H. Parving, W. F. Keane, Z. Zhang, S. Shahinfar, S. Snapinn, M. E. Cooper, W. E. Mitch, and B. M. Brenner Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy Circulation, August 24, 2004; 110(8): 921 - 927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. A. Koomans, P. J. Blankestijn, and J. A. Joles Sympathetic Hyperactivity in Chronic Renal Failure: A Wake-up Call J. Am. Soc. Nephrol., March 1, 2004; 15(3): 524 - 537. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Ruggenenti, N. Mise, R. Pisoni, F. Arnoldi, A. Pezzotta, A. Perna, D. Cattaneo, and G. Remuzzi Diverse Effects of Increasing Lisinopril Doses on Lipid Abnormalities in Chronic Nephropathies Circulation, February 4, 2003; 107(4): 586 - 592. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Sheetz and G. L. King Molecular Understanding of Hyperglycemia's Adverse Effects for Diabetic Complications JAMA, November 27, 2002; 288(20): 2579 - 2588. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. C. Sasso, O. Carbonara, M. Persico, D. Iafusco, T. Salvatore, R. D'Ambrosio, R. Torella, and D. Cozzolino Irbesartan Reduces the Albumin Excretion Rate in Microalbuminuric Type 2 Diabetic Patients Independently of Hypertension: A randomized double-blind placebo-controlled crossover study Diabetes Care, November 1, 2002; 25(11): 1909 - 1913. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Viberti, N. M. Wheeldon, and for the MicroAlbuminuria Reduction With VALsartan Microalbuminuria Reduction With Valsartan in Patients With Type 2 Diabetes Mellitus: A Blood Pressure-Independent Effect Circulation, August 6, 2002; 106(6): 672 - 678. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. H. Epstein, J. Almirall, T. Lopez, A. Chrysostomou, and G. Becker Spironolactone and ACE Inhibition in Chronic Renal Failure N. Engl. J. Med., February 7, 2002; 346(6): 456 - 457. [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Bakris A Practical Approach to Achieving Recommended Blood Pressure Goals in Diabetic Patients Arch Intern Med, December 10, 2001; 161(22): 2661 - 2667. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Herlitz, K. Harris, T. Risler, G. Boner, J. Bernheim, J. Chanard, and M. Aurell The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study Nephrol. Dial. Transplant., November 1, 2001; 16(11): 2158 - 2165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. W. Schrier and R. O. Estacio The Effect of Angiotensin-Converting Enzyme Inhibitors on the Progression of Nondiabetic Renal Disease: A Pooled Analysis of Individual-Patient Data from 11 Randomized, Controlled Trials Ann Intern Med, July 17, 2001; 135(2): 138 - 139. [Full Text] [PDF]
|
|
|
|
|
|
H. Buter, G. Navis, R. P. F. Dullaart, D. de Zeeuw, and P. E. de Jong Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM Nephrol. Dial. Transplant., April 1, 2001; 16(4): 771 - 775. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Melville, R Richardson, D Lister-Sharp, and A McIntosh Complications of diabetes: renal disease and promotion of self-management Qual. Saf. Health Care, December 1, 2000; 9(4): 257 - 263. [Full Text]
|
|
|
|
|
|
B. L. KASISKE, M. A. VAZQUEZ, W. E. HARMON, R. S. BROWN, G. M. DANOVITCH, R. S. GASTON, D. ROTH, J. D. SCANDLING JR., and G. G. SINGER Recommendations for the Outpatient Surveillance of Renal Transplant Recipients J. Am. Soc. Nephrol., October 1, 2000; 11 (90001): S1 - S86. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. van Woerkom and D. W. van Toorn A domestic fight or something else? Nephrol. Dial. Transplant., August 1, 2000; 15(8): 1253 - 1254. [Full Text] [PDF]
|
|
|
|
|
|
J. M. Wright Choosing a first-line drug in the management of elevated blood pressure: What is the evidence? 3: Angiotensin-converting-enzyme inhibitors Can. Med. Assoc. J., August 1, 2000; 163(3): 293 - 296. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hemmelder, D. de Zeeuw, and P. de Jong Antiproteinuric efficacy of verapamil in comparison to trandolapril in non-diabetic renal disease Nephrol. Dial. Transplant., January 1, 1999; 14(1): 98 - 104. [Abstract] [PDF]
|
|
|
|
|
|
T. Tikkanen, I. Tikkanen, M. D. Rockell, T. J. Allen, C. I. Johnston, M. E. Cooper, and L. M. Burrell Dual Inhibition of Neutral Endopeptidase and Angiotensin-Converting Enzyme in Rats With Hypertension and Diabetes Mellitus Hypertension, October 1, 1998; 32(4): 778 - 785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Orth and E. Ritz The Nephrotic Syndrome N. Engl. J. Med., April 23, 1998; 338(17): 1202 - 1211. [Full Text] [PDF]
|
|
|
|
|
|
G. L. Bakris, A. Mangrum, J. B. Copley, N. Vicknair, and R. Sadler Effect of Calcium Channel or ß-Blockade on the Progression of Diabetic Nephropathy in African Americans Hypertension, March 1, 1997; 29(3): 744 - 750. [Abstract] [Full Text]
|
|